Canada - English - Health Canada

teva canada limited - fentanyl - patch - 100mcg - fentanyl 100mcg - opiate agonists

Canada - English - Health Canada

teva canada limited - fentanyl - patch - 12mcg - fentanyl 12mcg - opiate agonists

United States - English - NLM (National Library of Medicine)

cima labs inc. - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz) - fentanyl 200 ug

United States - English - NLM (National Library of Medicine)

par pharmaceutical inc. - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz) - fentanyl 200 ug

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz) - fentanyl 800 ug

United States - English - NLM (National Library of Medicine)

depomed, inc. - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz) - fentanyl 100 ug - lazanda is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. patients considered opioid tolerant are those who are taking, for one week or longer, around-the-clock medicine consisting of at least: 60 mg of oral morphine per day, 25 mcg of transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60mg oral hydrocodone per day, or an equianalgesic dose of another opioid for a week or longer. patients must remain on around-the-clock opioids when taking lazanda. limitations of use: - not for use in opioid non-tolerant patients. - not for use in the management of acute or postoperative pain, including headache/migraine, dental pain, or in the emergency department [see contraindications (4)]. - as a part of the tirf rems access program, lazanda may be disp

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz) - fentanyl 100 ug

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 6.3 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 16.8mg;   - transdermal patch - 100 mcg/h - active: fentanyl 16.8mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 2.1mg;   - transdermal patch - 12 mcg/h - active: fentanyl 2.1mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.